This limitation is notable given evidence from experimental models where glucose-dependent insulinotropic peptide (GIP) agonists, such as tirzepatide, have been shown to promote tumor proliferation in a dose-sensitive manner, particularly in colorectal cancer cell lines [28]. The gene discussed is GIP; the disease is colorectal cancer.